Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Larger AUM within category. | ||
Cons | - | - |
INDMoney rank | 2/11 | 2/8 | ||
Category,Subcateogry | Equity,Sector - Financial Services | Equity,Sector - Healthcare | ||
Fund Age | 10 Years | 6 Years | ||
Fund Size | 7111 Cr | 4915 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.76% | 1.11% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | Nifty Financial Services TR INR | BSE Healthcare TR INR |
No of Holdings | 28 | 45 | ||
Top 5 Holdings | HDFC Bank Ltd (26%) ICICI Bank Ltd (14.29%) Kotak Mahindra Bank Ltd (9.74%) Axis Bank Ltd (9.74%) SBI Cards and Payment Services Ltd Ordinary Shares (2.52%) | Sun Pharmaceuticals Industries Ltd (13.5%) Dr Reddy's Laboratories Ltd (8.95%) Cipla Ltd (8.85%) Divi's Laboratories Ltd (6.71%) Aurobindo Pharma Ltd (5.3%) | ||
No of Sectors | 1 | 3 | ||
Top 3 Sectors | Financial Services (100%) | Health (90.94%) Basic Materials (6.08%) Financial Services (2.97%) | ||
Equity % | 84.85% | 98.28% | ||
Debt % | - | - | ||
P/E | 14.67 | 28.98 | ||
P/B | 2.22 | 4.16 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 10.01% | 4% | ||
3-Month Return | 9.69% | -4.29% | ||
6-Month Return | 5.4% | -5.71% | ||
1-Year Return | 21.27% | 21.02% | ||
3-Year Return | 18.86% | 23.46% | ||
5-Year Return | 24.73% | 26.57% |
Sharpe | 0.89 | 1 | ||
Alpha | 5.21 | 3.61 | ||
Beta | 0.83 | 0.93 | ||
Standard Deviation | 13.59 | 16.26 | ||
Information Ratio | 0.7 | 1.05 |
Description | SBI Banking & Financial Services Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Milind Agrawal | Dharmesh Kakkad |